Abstract:Abstract Mole mapping is an effective way to facilitate the early detection of melanoma in high-risk patients with multiple and/or atypical naevi. Current UK guidance recommends baseline photography (preferably dermoscopic) and clinical review for monitoring [National Institute for Health and Care Excellence. Assessing melanoma. Available at: https://www.nice.org.uk/guidance/ng14/chapter/Recommendations#assessingmelanoma (last accessed 20 March 2024)]. Our aim was to evaluate the use of a mole-mapping device with artificial intelligence (AI) in our National Health Service specialist pigmented lesion clinic and to compare this to standard medical photography. We carried out a pilot in January 2023 comparing our current photography software, Medical Image Manager (MIM), to the Canfield IntelliStudio Gen3 with DermaGraphix® (Canfield Imaging Systems, Fairfield, NJ, USA). The IntelliStudio combines a semiautomated photoacquisition system with mole-tracking software, allowing linked comparison of two-dimensional macro and dermoscopic images. The software flags new or changed lesions, and AI known as DExI version 1.0 (Dermatology Explained Intelligence) risk stratifies lesions as low or high risk for malignancy. The technology was assessed on its efficiency of use, its ability to identify new or changed naevi, and the accuracy of DExI. Twelve patients with multiple and/or atypical naevi were recruited: seven had multiple visits and eight had images captured with both the IntelliStudio and standard photography by the clinical photography team. On average DermaGraphix® was 5.4 times faster (P = 0.03) and needed 54% fewer clicks per lesion (P = 0.02) compared with MIM to assess all marked naevi, macro and dermoscopically. Consultants identified lesions for dermoscopy ranging from 2 to 32 per patient (mean 11.9). The number of lesions per patient identified by DermaGraphix® ranged from 152 to 2721 (mean 700) and naevi counts ranged from 45 to 749 (mean 255). The software flagged a few new and changed lesions in most patients with follow-up images. The toggle function allowed these to be rapidly identified as either benign inflammatory lesions or false positives, mainly attributable to variable body positioning and artefacts such as clothing. DExI identified 13 lesions as high risk for malignancy, 5 of which scored as low risk on another visit. These lesions were reviewed by dermatologists; all were clinically stable and benign. In conclusion, the IntelliStudio was considered a time-efficient and user-friendly system. A key benefit is the linking of dermoscopic images to the body map using automated markerless tracking, viewed on a single-page dashboard. Specialists can rapidly compare sequential images using the toggle function. Although this pilot suggests that DExI is not yet clinically reliable, a newer version is now available. We conclude that the IntelliStudio is a superior mole-mapping system compared with MIM for monitoring high-risk patients in a tertiary pigmented lesion clinic.

Usefulness of the ‘two‐step method’ of digital follow‐up for early‐stage melanoma detection in high‐risk French patients: a retrospective 4‐year study

Comparison of Extended Skin Cancer Screening Using a Three-Step Advanced Imaging Programme vs. Standard-of-Care Examination in a High-Risk Melanoma Patient Cohort

The Role of Digital Dermoscopy and Follow-Up in the Detection of Amelanotic/Hypomelanotic Melanoma in a Group of High-Risk Patients—Is It Useful?

Early diagnosis of melanoma: a randomized trial assessing the impact of the transmission of photographs taken with a smartphone from the general practitioner to the dermatologist on the time to dermatological consultation

Melanoma Detection by Non-Specialists: An Untapped Potential for Triage?

500pd new diagnostic techniques in early diagnosis of melanoma in situ

Distribution Quantification on Dermoscopy Images for Computer-Assisted Diagnosis of Cutaneous Melanomas

Clinician’s Ability to Identify Non-Melanoma Skin Cancer on 3D-Total Body Photography Sectors that Were Initially Identified during In-Person Skin Examination with Dermoscopy

Dermoscopy as a Tool for Identifying Potentially Metastatic Thin Melanoma: A Clinical–Dermoscopic and Histopathological Case–Control Study

Teledermoscopic triage of melanoma-suspicious skin lesions is safe: A retrospective comparative diagnostic accuracy study with multiple assessors

Early Melanoma Diagnosis With Sequential Dermoscopic Images

Exploring the feasibility of an artificial intelligence based clinical decision support system for cutaneous melanoma detection in primary care – a mixed method study

BT18 Is a mole-mapping device for patients with multiple and/or atypical naevi superior to standard photography in a National Health Service pigmented lesion clinic?

The Evolution of Melanoma Diagnosis: 25 Years Beyond the ABCDs

Exploring Patients’ Perceptions of One-step Surgery for Primary Cutaneous Melanoma: A Qualitative Study

The use of Reflectance Confocal Microscopy to diagnose Malignant Melanoma and Lentigo Maligna in the United Kingdom: A Prospective Observational Trial at a Single Centre

Clinical Utility of a Digital Dermoscopy Image-Based Artificial Intelligence Device in the Diagnosis and Management of Skin Cancer by Dermatologists

ACEMID cohort study: protocol of a prospective cohort study using 3D total body photography for melanoma imaging and diagnosis

New insights from non-invasive imaging: from prospection of skin photodamages to training with mobile application

Dermoscopic predictors of melanoma in small diameter melanocytic lesions (mini-melanoma): a retrospective multicentric study of 269 cases

Three-Point Checklist Dermoscopy for Melanoma Screening: Experience in Medical Students New to Dermatology